Kusajili – Clinical trials directory

Result of your search per sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company

Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company Update Il y a 4 ans

An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation To evaluate efficacy and safety of inotuzumab ozogamicin in combination with rituximab when used as induction therapy prior to consolidation with HD chemo and aSCT in subjects with relapsed/refractory...

Country None
organs None
Specialty None

Closed trial

More information